- Home
- ATAT vs FOLD Comparison
ATAT vs FOLD Comparison
Compare ATAT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAT
- FOLD
- Stock Information
- Founded
- ATAT 2013
- FOLD 2002
- Country
- ATAT China
- FOLD United States
- Employees
- ATAT N/A
- FOLD N/A
- Industry
- ATAT Hotels/Resorts
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- ATAT Consumer Discretionary
- FOLD Health Care
- Exchange
- ATAT Nasdaq
- FOLD Nasdaq
- Market Cap
- ATAT 4.8B
- FOLD 2.5B
- IPO Year
- ATAT 2022
- FOLD 2007
- Fundamental
- Price
- ATAT $40.01
- FOLD $7.78
- Analyst Decision
- ATAT Strong Buy
- FOLD Buy
- Analyst Count
- ATAT 2
- FOLD 9
- Target Price
- ATAT $37.40
- FOLD $28.00
- AVG Volume (30 Days)
- ATAT 1.5M
- FOLD 3.4M
- Earning Date
- ATAT 08-26-2025
- FOLD 11-05-2025
- Dividend Yield
- ATAT 1.13%
- FOLD N/A
- EPS Growth
- ATAT 31.52
- FOLD N/A
- EPS
- ATAT 1.38
- FOLD N/A
- Revenue
- ATAT $1,166,553,365.00
- FOLD $571,160,000.00
- Revenue This Year
- ATAT $32.05
- FOLD $20.98
- Revenue Next Year
- ATAT $22.51
- FOLD $20.74
- P/E Ratio
- ATAT $28.71
- FOLD N/A
- Revenue Growth
- ATAT 37.80
- FOLD 25.35
- 52 Week Low
- ATAT $19.70
- FOLD $5.51
- 52 Week High
- ATAT $40.37
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- ATAT 53.12
- FOLD 52.47
- Support Level
- ATAT N/A
- FOLD N/A
- Resistance Level
- ATAT $40.24
- FOLD $8.11
- Average True Range (ATR)
- ATAT 1.01
- FOLD 0.21
- MACD
- ATAT -1.38
- FOLD -0.33
- Stochastic Oscillator
- ATAT 99.10
- FOLD 94.99
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.